NCP 112
Alternative Names: NCP-112Latest Information Update: 02 Aug 2024
At a glance
- Originator DongKoo Bio&Pharma
- Developer DongKoo Bio&Pharma; Huons
- Class Eye disorder therapies; Peptides; Skin disorder therapies
- Mechanism of Action FPR2 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis; Xerophthalmia
Most Recent Events
- 11 Jul 2024 Phase-I clinical trials in Xerophthalmia (In volunteers) in South Korea (Intraocular) (NCT06263998)
- 22 Feb 2024 Huons plans a phase I trial for (In volunteers, In adults) in June 2024 (NCT06263998)
- 16 Dec 2021 Preclinical trials in Atopic dermatitis in South Korea (unspecified route) as of December 2021 (DongKoo Bio&Pharma pipeline; December 2021)